Healthcare & Life Sciences
Quell Therapeutics
United Kingdom
aliveseries-c-plus
series-c-plus
Stage
2
Investors
About
Develops engineered regulatory T cell (Treg) therapies aimed at downregulating pathological immune responses to treat immune-mediated diseases.
Explore Quell Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.